Scientific Research & Development

Scientific R&D services in the US — independent research labs, biotech research organizations, contract research organizations (CROs), and academic-affiliated institutions — represent over $250 billion in annual activity. Work spans pharmaceutical discovery, materials science, chemistry, physics, and emerging fields like quantum computing. Major players include IQVIA, Charles River Laboratories, and Recursion. The traditional discovery model is iterative and slow: hypothesize, design experiment, run, analyze, repeat. New-drug R&D averages $2.6 billion and 10-15 years per approved molecule. Materials discovery historically requires hundreds of physical experiments per candidate.

A concrete pattern for AI agents in research surfaced on May 7, 2026, when Google DeepMind detailed cross-domain results from AlphaEvolve — a Gemini-powered coding agent that autonomously searches for algorithmic improvements on problems with automatic evaluators. Documented wins include a 10x error reduction in quantum circuits, a 30% cut in DNA sequencing variant-call errors, resolved Erdős mathematics problems, improved Traveling Salesman Problem bounds, and 5% accuracy gains in natural-disaster risk prediction. Commercial deployments include Schrödinger (4x ML force field speedup in computational chemistry) and Klarna (doubled transformer model training speed in fintech ML infrastructure). AlphaEvolve sits closer to AlphaFold's product shape than to any conversational AI tool — frontier-model-plus-domain-specific-search-loop is now a validated template for AI in scientific R&D, alongside the iterative discovery model the industry has used for decades.

AlphaFold (Google DeepMind, Nobel Prize 2024) solved the protein-folding problem and accelerated drug discovery industry-wide. Isomorphic Labs (Alphabet spin-off) uses AlphaFold derivatives for de novo drug design. Recursion Pharmaceuticals operates AI-driven phenomic platforms generating petabytes of biological imagery. Materials science platforms — Citrine, Microsoft's MatterGen, Schrödinger — propose novel compounds optimized for target properties. Generative chemistry tools (Insilico Medicine, Atomwise) screen billions of virtual molecules. NVIDIA Clara and BioNeMo provide foundation-model infrastructure for life-science research.

Lab technicians and bench scientists doing repetitive screening face automation pressure; computational biologists, AI-savvy chemists, and platform engineers are in extreme demand. Drug-discovery timelines compress: AI-designed candidates reach IND filing in 1-2 years instead of 4-6. CROs face structural pressure as in-silico screening reduces wet-lab volume. Academic researchers need both domain expertise AND ML literacy to remain competitive for grants. New roles: AI-for-science research scientist, foundation-model fine-tuning specialist for biology/chemistry, lab-AI integration engineer.